LUCAS trial: Bevacizumab, ranibizumab comparable in treat-and-extend protocol

NEW ORLEANS — At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to an inject-and-extend protocol for the treatment of age-related macular degeneration, according to a speaker who gave results of the LUCAS trial here. “This is the first multicenter study where an inject-and-extend protocol has been utilized for the treatment of exudative AMD,” Karina Berg, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Full Story →